Please login to the form below
ICS
This page shows the latest ICS news and features for those working in and with pharma, biotech and healthcare.
AZ, Amgen’s investigational asthma drug comes good in phase 3
The phase 3 NAVIGATOR trial evaluated tezepelumab plus standard of care, which included medium- or high-dose inhaled corticosteroids (ICS) plus at least one controller medication, with or without oral corticosteroids
Latest news
-
Novartis reveals full phase 3 results for Enerzair Breezhaler
and a high dose of an inhaled corticosteroid (ICS), who had experienced one or more asthma exacerbations in the previous year. ... symptoms despite receiving a LABA/ICS, which is the standard of care,” said Huib Kerstjens, head of the Department of
-
AZ builds case for its COPD triple as it chases GSK’s Trelegy
Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s
-
Sanofi's Dupixent gains asthma approval in Europe
inflammation. However, Dupixent can only be used in this setting when patients have used at least one other maintenance treatment, along with high dose inhaled corticosteroid (ICS).
-
AZ prepares to file COPD triple, taking on rival GSK
The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –
-
AZ rival to GSK’s COPD drug Anoro fails head-to-head test
The real battleground between the two companies is expected to be three-drug combinations for COPD, with an inhaled corticosteroid (ICS) added to the LAMA/LABA duo.
More from news
Approximately 1 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
GSK forges ahead with its dynamic COPD and asthma portfolio
For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.
-
The roaring ‘20s and Generation Z
For instance, the draft NHS Standard Contract 2020/21, published in December 2019 will see NHS Trusts and CCGs being contractually obliged to work collectively as a single local ICS system, ... Over the next five years at least, campaigns and messaging
-
NHS regional footprints
CCGs in action. In Nottinghamshire, six CCGs have joined forces to lead the strategic development of integrated care within the geographical area originally allocated to the Nottinghamshire ICS.
-
Deal Watch table for August 2014
600. TARIS Biomedical/ Allergan. Company acquisition. LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Delivering true value: what does it mean for KAM in cancer care?
The real challenge of working with these new ICS accounts and other integrated care organisations is very much about teamwork.
-
How will the Tories’ historic win shape the NHS?
Integrated care. The Tories’ win has provided assurance that there will be 100 percent Integrated Care System (ICS) coverage across England by April 2021, as promised in the Long-term Plan. ... We wait to see if it will mean a growth in CCG and ICS
-
2019: A pivotal year for the NHS
Structure. The Long-term Plan stated that, by April 2021, all areas of England will be covered by an Integrated Care System (ICS), with typically just one Clinical Commissioning Group (CCG) ... It means that hospitals and CCGs must now work together to
-
Early diagnosis underpins NHS cancer strategy
The Cancer Alliances will advise Sustainability and Transformation Partnership (STP) and Integrated Care System (ICS) board members on cancer services and help to ensure that local cancer strategies are delivered.
-
What role for pharma in helping to deliver integrated care?
Phil explained how Dorset ICS runs “a family budgeting system”, where money has already moved from one organisation to another to achieve balance across the system. ... To hear more from Dr Phil Richardson, of Dorset ICS, regarding integrated care
More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Communique - Communiqué Awards
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
